Initial focus on $1 Billion Lung Cancer Market
Deaths Per Year
Potential Additional Indications US only
Investors & Partners
AcuityBio is developing a first in class therapeutic orphan drug delivery technology. We are focused on developing a drug-eluting implant to treat residual occult tumors left behind after surgical resection. We are currently moving our first product candidate through a carefully planned preclinical program in preparation for clinical trials. AcuityBio is actively seeking investment, co-development, and licensing partners.
Contact us here